Yesterday, Thursday, February 22, Nvidia (NVDA) gained 16.40% at the close after beating Wall Street expectations on earnings and revenue after the market close on Wednesday. And then raising guidance for the rest of 2024. But what most interested me on Thursday were what tech stocks Nvidia carried higher with it–and which stocks it didn’t.
Well, optimistic analysts just weren’t optimistic enough about Nvidia’s (NVDA) fourth quarter 2023 earnings. The company reported adjusted earnings of $5.16 per share on revenue of $22.1 billion. Analysts were expecting earnings of $4.60 a share and revenue of $20.4 billion.
After yesterday’s earnings report–the company beat Wall Street estimates for the quarter–and radically lower guidance for next quarter and the rest of 2024–total billings for next quarter will grow by just 2% to 4% and revenue for all of 2024 will grow by just 15% to 16% from 2023–shares of Palo Alto Networks (PANW) took a big hit right between the eyes. The stock fell 28.44% at the close and lost $104.12 a share to $261.97. What do I recommend? I’d say “buy” with a couple of caveats. Why buy?
Lynas, one of the largest producers of rare earth minerals outside of China (and one of only two non-Chinese processors of rare earth minerals) is my sixth Penny stock pick for my Special Report.
I expect the market reaction to Nvidia’s (NVDA) earnings report, to be released after the close on Wednesday, February 21, to tell investors a lot about the short-term direction of this stock market. We’re likely to learn more, however, from the reaction to an Nvidia beat rather than from an earnings miss.
Can you hear the barkers yelling to the crowd? It’s Wall Street analysts rushing to raise their target prices for Nvidia (NVDA) ahead of next week’s quarterly earnings report. On February 21, after the close, Nvidia is expected to report earnings of $4.18 share, up from $0.65 a share in the quarter a year ago, on revenue of $20.5 billion. And even though the stock is up 47% for 2024 as of the February 15 close and up 219% for the last year, Wall Street analysts are rushing to increase their target price on the shares.
My 10 Penny Stock Homeruns Pick #5: Vestas Wind Systems (VWDRY).
Technically, the Vestas Wind Systems ADR (VWDRY) isn’t a penny stock. By the strict definition, a penny stock sells for $5 or less and the Vestas ADR closed on $9.06 today, February 14. But I included Vestas in my previous penny stock list back on July 11, 2022, even though the stock closed at $7.80 that day. With the company reporting a return to profitability for 2023 in its fourth quarter earnings report released today, I think Vestas has (finally) turned the corner. And, frankly, I just don’t want drop it from this list just as things get good again for the company and its investors. (Vestas is a member of my Jubak’s Picks Portfolio. The position is up 65.6% since initiation on March 4, 2019.) Tomorrow, February 15, I’ll also add Vestas to my long-term 50 Stocks Portfolio.
I’m adding a bit more timeliness to this weekly video slot by moving away from my Trend of the Week series and changing it to “Hot Button Moves NOW” to highlight action you can take now.. Today’s Hot Button Moves NOW video is: Put Options on the S&P Regional Banking ETF (KRE). This is a play on continued trouble in the regional banking sector. New York Community Bank has just been downgraded to junk by Moody’s, (due to its real estate loan portfolio) and has dropped by 60%, taking the regional bank sector along with it. Last Monday I bought puts for April 24 at 14 strike price for $2.09 each and the put price has gone through the February 7 date when I recorded this video. I don’t think this is the end of regional bank trouble so I’ll be holding on to these puts until the bad news subsides. This is a good way to take advantage of some of these dips in the market and hedge risks. For more options and volatility stocks, subscribe to JubakAM.com.
Nearly 20% of outstanding debt on US commercial and multifamily real estate-— $929 billion–will mature this year, requiring refinancing or property sales, Bloomberg reported today. The volume of loans coming due has swelled 40% from an earlier estimate by the Mortgage Bankers Association of $659 billion, a surge attributed to loan extensions and other delays rather than new transactions. About $4.7 trillion of debt from all sources is backed by U.S. commercial real estate. An estimated $85.8 billion of debt on commercial property was considered distressed at the end of 2023, MSCI Real Assets reported, citing an additional $234.6 billion of potential distress.
Today’s Quick Pick is CVS Health (CVS). CVS owns a unique combination of healthcare delivery channels. Drugstores, yes–9,000 of them. But the company also owns health insurance company, Aetna, and Caremark, the largest pharmacy benefit manager. And recently it moved into the primary care marketplace through its acquisition of Oak Street. The company reported earnings on Wednesday, February 7, and the stock was up about 3.25% after that. While the earnings were good, (they beat by $0.13) the guidance is what is important here. The company projected higher costs for 2024 and cut guidance for GAAP earnings ($7.06) and adjusted earnings ($8.30). The reason the stock went up despite these cuts is that everyone was expecting DEEPER cuts to guidance. CVS has been signaling for weeks that rising costs in 2024 could be painful for the healthcare sector as a whole, and the relatively minor cuts in guidance led to a rally in the stock. Morningstar calculates a fair value for CVS Health of $103 a share. The stock closed at $76.32 on February 9. The stock also pays a 2.36% dividend. The stock is a member of my Dividend Portfolio. That position is up 31.25% since October 28, 2020.
